Welcome to our dedicated page for Cellectar Biosciences SEC filings (Ticker: CLRB), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Cellectar Biosciences filings document the regulatory record of a Delaware clinical biopharmaceutical company developing cancer therapies through its PDC platform. Current reports furnish quarterly and annual financial results, corporate updates, Regulation FD disclosures, and other events related to iopofosine I 131, CLR 125 and regulatory communications for its oncology programs.
Registration statements and material-event reports describe securities offerings, shelf registration activity, registered direct offerings, private placements, common stock, pre-funded warrants, milestone-based warrants and warrant exercise inducement transactions. The filing record also covers exhibit disclosures, Inline XBRL cover data, incorporation status, securities-law classifications and financing agreements that shape CLRB's public-company capital structure.
Janus Henderson Group plc reported beneficial ownership of 798,382 shares of Common Stock of Cellectar Biosciences, Inc. The filing states this equals 9.99% of the class and discloses additional holdings of 1,051,520 pre-funded warrants and 1,886,792 Series A, B, and C warrants each, with exercise limitations described in the filing. The disclosure is filed on behalf of Janus Henderson and affiliated asset managers and is signed on 06/05/2026.
Cellectar Biosciences is registering the resale by selling stockholders of up to 51,998,413 shares of its common stock pursuant to a May 4, 2026 private placement and related transactions.
The prospectus states the company will not receive proceeds from these resales, although it will receive proceeds from any cash exercise of Placement Agent Warrants, Pre-Funded Warrants or other Warrants; the resale registration satisfies contractual obligations under the Purchase Agreements.
Shares outstanding were 4,240,129 as of April 30, 2026 (adjusted to 5,858,182 to give effect to the RDO); the filing shows pro forma outstanding shares of 57,856,595 assuming full exercise of the registered instruments.
Cellectar Biosciences, Inc. has filed an amended S-1 to register the resale of up to 51,998,413 shares of common stock for existing selling stockholders. These shares include stock already issued in a May 2026 private placement and shares issuable upon exercise of Pre-Funded, Series A, Series B, Series C and Placement Agent Warrants.
The company will not receive proceeds from stockholder resales but may receive cash if the various warrants are exercised. After full exercise of the registered warrants, total common shares outstanding would rise to 57,856,595. The filing also details significant financing risks, including expectations of continued operating losses and substantial doubt about the company’s ability to continue as a going concern without additional capital.
Cellectar Biosciences is asking stockholders to approve a broad set of proposals at its July 7, 2026 virtual annual meeting, combining routine governance items with significant equity actions. Two Class III directors are up for election and Deloitte is proposed for ratification as auditor. Stockholders are asked to increase the 2021 Stock Incentive Plan share pool by 2,000,000 shares; as of May 15, 2026 only 100,651 shares remained available, with 7,991,812 shares of common stock outstanding as of the May 19, 2026 record date. A non-binding “say on pay” vote will be held on named executive officer compensation.
The company also seeks approval under Nasdaq rules for the exercise of warrants to purchase up to 39,618,078 shares of common stock issued in a May 2026 private placement and related transactions, which generated approximately $30.7 million of gross proceeds and could yield up to about $105.0 million in additional cash if all such warrants are exercised for cash. An adjournment proposal would allow more time to solicit votes if needed for the warrant exercise approval. The proxy explains that failure to approve the warrant exercise could limit future funding, while approval would create substantial potential dilution for existing holders.
Cellectar Biosciences, Inc. has filed an S-1 to register the resale of up to 51,206,051 shares of common stock by selling stockholders. These shares include stock already issued in a May 2026 private placement and shares issuable upon exercise of pre-funded and Series A, B and C warrants.
The company will not receive proceeds from stockholder resales, but could receive cash if warrants are exercised. If all warrants are exercised, shares outstanding would rise to 57,064,233 from 5,858,182 adjusted shares as of April 30, 2026. Cellectar highlights substantial regulatory, clinical and manufacturing risks around its lead cancer candidate iopofosine I 131.
As of December 31, 2025, cash was about $13.2 million, which management believes funds basic operations into the second quarter of 2027. The company warns of substantial doubt about its ability to continue as a going concern without additional capital and outlines extensive risks related to financing, approvals, competition and ongoing compliance.
Cellectar Biosciences, Inc. is soliciting proxies for its 2026 Annual Meeting to be held virtually on July 7, 2026. The meeting will vote on director elections and six proposals, notably: (1) election of two Class III directors; (2) a 1,000,000‑share increase to the 2021 Stock Incentive Plan; (3) ratification of Deloitte & Touche, LLP; (4) an advisory vote on executive compensation; (5) approval to permit exercise of warrants to purchase up to 39,618,078 common shares under Nasdaq rules; and (6) an adjournment authorization to solicit additional proxies if needed. Shares outstanding were 7,991,812 as of May 19, 2026. The proxy package and the Company’s Annual Report on Form 10-K (as amended) are available online at the meeting portal.
Cellectar Biosciences announced upcoming board changes and a new consulting role for an exiting director. Stefan D. Loren, Ph.D. informed the board he will not stand for reelection as a Class III director at the 2026 annual meeting, and his current term will end at that time. The company states his decision is not due to any disagreement over operations, policies, or practices.
Cellectar entered into a one-year consulting agreement with Dr. Loren, effective July 8, 2026, under which he will receive $15,000 per quarter and a stock option grant for 15,000 shares at the end of the term, with all his granted options remaining exercisable for 10 years from their grant dates. Separately, under a previously disclosed board designation side letter linked to a May 4, 2026 securities purchase agreement, Nantahala Capital Management selected Andrew Gu as its board designee. The board appointed Gu on May 18, 2026 as a Class III director and member of the Audit Committee. The company notes he has no disclosable related-party transactions or family relationships with its directors or officers.
Cellectar Biosciences, Inc. reported a first quarter 2026 net loss of $5.65 million, improving from a loss of $6.60 million a year earlier, with basic and diluted net loss per share of $1.33 on 4,240,129 weighted-average shares. Operating expenses were $5.79 million, mainly for research and development and general and administrative costs. The company ended March 31, 2026 with $8.35 million in cash and cash equivalents and total assets of $11.12 million.
Cellectar highlighted positive 12‑month follow-on data for iopofosine I 131 in relapsed/refractory Waldenström Macroglobulinemia, including an overall response rate of 83.6%, median progression-free survival of 13.5 months, and a disease control rate of 98.2%. It also completed a financing of up to $140 million to support a confirmatory study and a planned FDA accelerated approval filing, and dosed first patients in a Phase 1b trial of CLR 125 in triple negative breast cancer.
Cellectar Biosciences reported a Q1 2026 net loss of $5.65M, narrower than $6.60M a year earlier, as operating expenses fell to $5.79M. Cash and cash equivalents were $8.35M versus $13.20M at December 31, 2025, with operating activities using $4.85M of cash in the quarter.
The company remains a pre‑revenue, late‑stage oncology biotech with an accumulated deficit of about $275M and substantial reliance on external financing. Management disclosed substantial doubt about its ability to continue as a going concern beyond the second quarter of 2027 without additional actions, despite approximately $37M of liquidity as of the financial statement issuance date.
Clinically, Cellectar highlighted strong follow‑up data from its CLOVER WaM trial in relapsed or refractory Waldenstrom’s macroglobulinemia, including an overall response rate of 83.6% and major response rate of 61.8%, and it is preparing a Phase 3 confirmatory study supported by a financing that includes up to $105M in milestone‑based securities.